BACKGROUND: Although the prevalence of dementia increases exponentially with age, some individuals reach >100 years with fully retained cognitive abilities. To identify the characteristics associated with the escape or delay of cognitive decline, we initiated the 100--plus Study (www.100plus.nl).
address online and we approach a prospective study participant by letter. When they express their interest in study participation and inclusion criteria are met, we schedule two baseline visits. (See supplementary material for detailed recruitment procedures).
Baseline visit: A researcher, trained to perform standardized visit procedures, will visit
the centenarian. The baseline visit (T0) consists of two visits. The first baseline visit takes approximately 2 to 3 hours, and comprises obtaining informed consent for study inclusion, a life--history interview, an assessment of genealogy, and an assessment of current health and medical history ( Table 1) . The second baseline visit, approximately one week after the first, takes approximately 1.5 hours: during this visit we subject the centenarian to a battery of neuropsychological tests and we measure grip strength and blood pressure ( Table 2) . During the first baseline visit we inform participants of optional parts of the 100--plus Study: post--mortem brain donation, PET--MRI or PET--CT imaging and feces collection. Once a centenarian volunteers to participate in these parts of the 100--plus Study, we obtain informed consent for these study parts separately.
Follow--up visits:
During yearly follow--up visits (T1, T2…), which take approximately 2 hours: we inform about possible changes in cognitive functioning that took place in the last year, we update the interview questionnaire and re--administer the complete cognitive test battery and physical measurements (Table 1, 2) . Follow--up is continued until the participant is no longer willing/able to participate. When the MMSE score declines ≤20 there is evidence of clear cognitive impairment [22] , and subjecting a centenarian to a neuropsychological testing battery becomes more complicated. Follow-up visits by a researcher may no longer be constructive, and in such cases, we follow--up by informant questionnaire. To ensure up--to--date cognitive health measurements of brain donors, we administer telephone and informant questionnaires 6 months after the annual visit (T0.5, T1.5…). For a diagram of procedures see Figure  2 . We ask informants to inform us when a participant dies and about the events that preceded death.
Data collection
Centenarian presentation: During each visit, the researcher subjectively estimates the visual, hearing and mobility function as "good", "moderate", "poor" or "very poor", according to the determinants listed in Table 3 . We collect the following variables regarding centenarian presentation: the level of independence during activities of daily living (ADL) using the Barthel Index [23] , an estimation of the total hours of care/assistance needed per week; category housing situation, (independent-dependent); grip strength, systolic and diastolic blood pressure; heartbeat; and napping habits and sleep quality (Pittsburg Sleep Quality Index questionnaire [24] ). We assess whether the centenarian suffers from symptoms of depression [25, 26] by administering the 15--item geriatric depression scale . We ask about recent weight loss, current weight and length and active infections.
Medical History: For each centenarian we obtain a General Practitioner (GP) summary report, which lists diagnosed conditions and prescribed medications. These conditions are categorized by a dedicated GP ( Table 4 ). After the centenarian died, we request a second synopsis from the GP, describing the medical proceedings until death. In a self-report medical history questionnaire, we inquire about blood pressure, heart disease; stroke (CVA) or TIA; tumors, head injuries, incontinence, dental condition, mental health problems, hospital visits, surgeries/anesthesia. We estimate BMI at midlife by recording self--reported weight and length at middle--age (~50 years). For centenarian--females we inquire about age at menarche, onset of menopause, number of pregnancies and/or miscarriages.
Cognitive profiling:
We objectively evaluate cognitive functioning using a comprehensive neuropsychological test battery that addresses memory, attention and/or concentration, pre--morbid intelligence, language, executive and visuo--spatial functions ( Table 2) . To assess overall cognitive functioning we administer the Mini--Mental State Examination (MMSE) [22] . To generate a total MMSE score for all centenarians, also when geriatric sensory impairments led to missing items on the MMSE, we adjust scores using multiple imputation (see supplementary material).
Additionally, at every visit the researcher formulated a subjective impression of cognitive functioning of the centenarian (see supplementary material). During each research visit we ask a proxy to fill in the Dutch version of the abbreviated form of the Informant Questionnaire on Cognitive Decline (IQ--CODE) to indicate whether the centenarians experienced cognitive decline in the past ten years (or, in case of follow--up visits, during the past year) [27, 28] .
Lifetime/demographic characteristics:
To investigate the family genealogy and disease occurrence, we draw a pedigree including children, siblings, parents and grandparents, their (maiden) names, gender, birth years, age at death and cause of death, occurrence of dementia/cognitive decline. To determine socio--economic background (SEB) and socioeconomic status (SES) we inquire about the main occupation of the father and mother of the centenarian, the main occupation of the centenarian him/herself at adulthood and the main occupation of their partner(s). We inquire about the education level and the number of years education followed. These were classified according to (I) ISCED 1997 [29] and according to Dutch 1971 census [30] .
Lifetime habits:
We address smoking habits and alcohol consumption (see additional data). We administer the Cognitive Activity Questionnaire (CAQ) [31, 32] to investigate 1) cognitive stimulating experience during adult life (from childhood to 50 years) and 2) current cognitively stimulating experience.
Data--collection of first degree living centenarian--relatives and partners:
For centenarian siblings and their partners, we administer the MMSE at the study inclusion visit and we record the genealogy at the level of the centenarian--generation. We will yearly monitor changes in physical well--being and in cognitive health using TICS--M and IQ--Code--N. We ask centenarian--children and partners to fill in an abbreviated version of the centenarian questionnaire; we record the genealogy of the centenarian--generation, no cognitive testing will be administered; we will not follow--up centenarian--children and their partners ( Table 1) .
Biomaterials
Biomaterial collection: During baseline visits, we collect a blood sample from all subjects for DNA isolation, peripheral blood mononuclear cells (PBMCs), plasma, serum, and when consent is given for generation of induced pluripotent stem cells (iPSCs). DNA samples are currently used for APOE genotyping, GWAS, whole exome sequencing (WES) and Sanger sequencing. Furthermore, all centenarians are informed about the option for feces donation for gut microbiome analysis, PET--MRI or PET--CT brain scans for in vivo detection of amyloid beta presence and structural brain imaging. We also inform about the option of post--mortem brain donation. Brain autopsies are performed in collaboration with the Netherlands Brain Bank [33, 34] .
Data storage: OpenClinica open source software (version 3.1 onwards) is used for data
management [35] . Biomaterials are stored in the biobank of the VUmc.
RESULTS/COHORT DESCRIPTION:
Included centenarians: Between January 1 st 2013 and June 21 st 2017, 773 centenarians were approached for study--participation of which 302 (40%) met study--inclusion criteria and were included in the study (Figure  4 ). As soon as the data collection from the first 300 centenarians was complete, we generated a first data--freeze on June 21 st 2017. Of these 300 centenarians, 83 agreed to brain donation (28%); 37 of these had come to autopsy. The mean age at inclusion of centenarians was 101.3±1.7 years ( Figure 5A) .
The majority of centenarians were born between 1910 and 1917 ( Figure 5B ). For all cohort descriptives see Table 5 .
Presentation at baseline: Subjective researcher estimates of geriatric sensory
impairments indicated that 87% of the centenarians had moderate--good hearing abilities (Figure 6A) , that 77% of the centenarians had moderate--good vision (Figure 6B) , and that 80% of the centenarians were independently mobile ( Figure  6C ). The majority (52%) of the centenarians in the cohort lived independently (i.e. community dwelling without assistance, or independent in a residence with available services), 42% lived in private quarters in a residential care center, while only 1.7% of the centenarians lived in a nursing home ( Figure  6D ). Centenarians scored a median of 15 points (IQR: 12--18), on the Barthel index: 45% of the centenarians scored between 15--19, which indicates a need for minimum help with activities of daily living (ADL), while 32% scored 20 points which indicates they are fully independent in ADL ( Figure 6E ). The centenarians in the cohort have no or very few symptoms of depression: they scored a median of 2 points on the 15--items version of the Geriatric Depression Scale (IQR: 1--3), and scores <5 indicate no evidence for depression [25] (Figure 6F) .
Disease prevalence and multi--morbidities: We analyzed the conditions listed in the GP
medical records from 209 centenarians (Table 4 ). At baseline, centenarians were diagnosed with or had symptoms of on average 3.9±1.6 morbidities ( Figure 6G) .
Musculoskeletal disease and hypertension were more prevalent in females (73% vs. 39% and 54% vs. 34%), while cardiovascular conditions were more prevalent in males (68% vs. 56%). Most aging--associated diseases were first mentioned in the GP report when the centenarian was >90 years, suggesting a seemingly high age at onset. As we cannot correct for methodical differences in data collection by GPs, we were not able to perform a systematic comparison with disease incidence statistics from prospective cohort studies.
Cognitive function (MMSE):
Overall cognitive functioning of 300 centenarians was tested by the MMSE, and scores were imputed to adjust for missing items due to hearing or vision impairments (see Methods). Of all centenarians, 206 (69%) had no missing items on the MMSE and scores were not imputed; for 10 centenarians (3%), hearing or vision impairments led to too many missing items: these were not adjusted by imputation and excluded from analysis. The MMSE included missing items for 84 centenarians (28%) and scores were imputed: imputation increased MMSE scores <1 point for 37 centenarians (12%), 1--2 points for 25 centenarians (8%), 2--3 points for 14 centenarians (5%), 3--6 points for 8 centenarians (3%). At study inclusion, the MMSE score of the 100--plus Study cohort was on average 24.3 ±4.23 points and (median score: 25, IQR: 22.0--27.5) ( Figure 7A ). For 287 centenarians, a trained researcher estimated cognitive health. The large majority (83%) of the centenarians was estimated to be cognitively healthy, and this group scored a median of 26 points on the MMSE (IQR: 23.5--28). This was significantly higher than the median MMSE score of 19 (IQR: 16.4--22) by the 41 centenarians for whom cognitive health was "doubted" (p=4x10 --3 , two--tailed t--test with unequal variance), and the median MMSE score of 8 centenarians who were estimated to have "probable cognitive impairment" was 16.4, (IQR: 12.8--17) (Figure 7B ).
MMSE and mortality rates:
Within the group of 293 participants for which a baseline MMSE was available, there were 67 deaths that occurred before a next planned visit: the planning of a next visit was used to confirm which centenarians were still alive and who had died (for mortality rate calculation procedures, see supplementary material).
The overall mortality rate in the first year after inclusion was 0.24 (95%CI: 0.17--0.32), specifically, the 135 centenarians who scored ≥26 on the MMSE at baseline had a mortality rate of 0.19 (95%CI: 0.11--0.29), while the 158 centenarians with MMSE scores <26 had a mortality rate of 0.29 (95%CI: 0.19--0.43) (p=0.075). In the second year after baseline, the mortality rate increased to 0.32 (95%CI: 0.20--0.49); specifically, the mortality rate of the centenarians who scored ≥26 points at baseline remained at a low 0.19 (95%CI: 0.08--0.37), while the mortality rate of centenarians who scored <26 points increased to 0.54 (95%CI: 0.29--0.90) (p=3.0.x10 --3 ) ( Figure 7C) . For conversion to mortality percentages see Table 4 .
Education: We retrospectively compared centenarian--education levels with 54--61 year--
olds as reported in the Dutch population in the 1971 census [36] , these individuals were from the same birth--cohort as the centenarians (1910--1916) . Both male and centenarian--females attained significantly higher levels of education compared to their birth--cohort in the 1971 census [30] (p<1x10 --5 , Mann--Whitney U test) (Figure 8A ).
Workers and self--employed persons with little education were overrepresented in the 20% non--responders in the 1971 census, suggesting that this is a conservative estimate of the differences [30] . 
Smoking behavior and alcohol consumption: Retrospective comparison of smoking
behavior suggests that centenarians smoked less than a representative sample of Dutch individuals born between 1909--1923, as indicated a 1958 survey [38, 39] . Of the centenarian--males 67% indicated to have smoked regularly or often during an extended period in their life, while 91% of the birth--cohort males reported to smoke in 1958. Of the centenarian females, 15% indicated to have smoked regularly or often while 32% of the birth cohort females smoked. Alcohol consumption was common: only 11% of the centenarian--males and 22% of the centenarian--females indicated to never consume alcohol, similar to 14% of male--abstainers and 21.8% female--abstainers among the birth cohorts in the 1958 survey [38] , whereas 54% of the centenarian--males and 31% of the centenarian--females indicated to consume alcohol regularly or often.
Marriage and children: Centenarians had on average 3.9±2.2 children, which was more
than the average 3.5±2.5 children from 860 Dutch parents born between 1910--1915 [40] (p=0.03, Mann--Whitney U) ( Figure  9C ). Overall, 91% of the centenarians was ever-married, and 86% had one or more children. Of the centenarian females, 16.5% remained childless (36/219), similar to the 16% childless females born between 1915--1919 [41] . Five males in the cohort (6%) remained childless (birth--cohort data not available [41] ). APOE allele frequency: APOE was genotyped for 266 centenarians (Figure 9 ). We observed that the centenarians were >2--fold more likely to carry an APOE--ε2 allele than to 2,233 relative to Dutch population controls aged 60--80 years [42] . Specifically, centenarians are 2.5--fold more likely to be genotyped APOE--ε2/ε3 ( Table 5 ). In contrast, centenarians are >2--fold less likely to carry an APOE--ε4 allele compared to the Dutch population; specifically, centenarians are 2.8--fold less likely to be genotyped APOE--ε3/ε4 and 6.7--fold less likely to be genotyped APOE--ε4/ε4. The allele frequency of the APOE ε3 allele was identical for both cohorts.
DISCUSSION:
Here, we present the 100--plus Study cohort of cognitively healthy centenarians based on the first 300 centenarians included in the 100--plus Study.
On average, the centenarians in the 100--plus Study cohort have a high performance on the MMSE; the large majority is independent and retained hearing and vision: Our inclusion criteria of "self--reported cognitive health, which is confirmed by a proxy" sorted centenarians with a relatively high level of overall cognitive functioning. The cohort scored an average of 24.3 ±4. 23 [45] ). The overall cognitive performance of the 100--plus cohort participants is similar to "community--dwelling cognitively healthy centenarians" from the Georgia centenarian Study [46] , and "cognitively healhy" Japanese centenarians, who repectively scored a mean of 24.8 points and 22.3±3.32 points on the MMSE [47] .
Next to their retained cognitive functioning, the large majority of the centenarians had moderate--good hearing and vision abilities, they were independently mobile, they enjoyed a relatively high level of independence in activities of daily living (ADL), and had no or few symptoms of depression. Centenarians were either community dwelling or lived independently in a residence or in a care center with available services. Together, these findings echo that the 100--plus Study cohort represents high--performing, independent Dutch centenarians.
Cognitive performance is associated with mortality:
The high cognitive and overall performance of our cohort was related with a low mortality. The first year after baseline, the mortality of the centenarians in our cohort was 20.5%, which is 2--fold lower than the 40% mortality of the overall Dutch centenarian population [48] . In the second year after baseline mortality increased to 28%: specifically, centenarians with high cognitive functioning retained a low mortality of 17%, while centenarians with a decline in cognitive functioning had a mortality rate of 42%. Our results confirm that there is an overlapping etiology of maintained cognitive and overall health, and cognitive functioning might be employed to predict overall decline and mortality [49, 50] . The longitudinal set--up of our study will allow us to monitor changes in cognition in combination with other factors of overall health that occur between baseline and death to identify to which extent centenarians escaped or delayed cognitive impairment.
The 100--plus cohort is 2--fold enriched with males: The fraction of centenarian--males is 27%, twice the fraction of males (14.4%) in the total Dutch centenarian population on January 1 st 2017 [51] . Indeed, since dementia--prevalence in centenarian populations is consistently lower in males (~40%) than in females (~60%) [52, 53] , we had on forehand expected that our inclusion criteria of "self--reported cognitive health, which is confirmed by a proxy" might sort relatively more centenarian males than females. Based on the fraction of centenarian males in the population (14.3% in 2017) and lower dementia prevalence in males (40% vs 60%), we estimated that the fraction of males in the 100-plus Study cohort should be approximately 20%. This suggests that dementia incidence does not fully explain the excess of males in our cohort, which leaves room for, for example, the influence of a participation bias and a better general well--being of centenarian males [54] .
Disease in male and female centenarians:
Despite the cognitive health of the centenarians in the 100--plus Study cohort, they were diagnosed with on average four morbidities at baseline. Previous studies have shown that females are more prone to develop chronic nonfatal conditions such as dementia, arthritis and osteoporosis [55] , while males are more likely to develop fatal conditions, such as cardiovascular disease and cancer [56, 57] . In agreement with these studies, we found that the females in the 100--plus Study cohort had a higher prevalence of musculoskeletal diseases and hypertension while males had a higher prevalence of heart disease and CVA/TIAs. The 100--plus Study cohort is equally depleted with the APOE--ε4 allele compared to other centenarian cohorts, but it is strongly enriched with the neuroprotective APOE--ε2 allele: The 100--plus Study cohort was 2.3--fold less likely to carry the APOE--ε4 AD--risk allele compared to their birth cohort at 60--80--years (OR=0.44, p=6.3x10 --7 ) [42] . This is in complete concordance with the depletion observed in a meta--analysis of 2,776 (mostly Caucasian) centenarians and 12,000 controls (OR=0.43, p<1x10 --3 ) [58] . It is well established that carrying one or two APOE--ε4 alleles is associated with respectively a 3--5 and 10--30--fold increased risk of developing AD. Depletion of the APOE--ε4 allele in centenarians supports an association of the ε4 allele with mortality at younger ages: carriers dropped out of the population during aging [59] , leading to a depletion of the APOE--ε4 allele in centenarians that is consistent across studies.
On the other hand, carrying one protective APOE--ε2 allele is associated with a 2--fold decreased lifetime risk of developing AD [60, 61] . But the large centenarian meta-analysis indicated that the protective aspect of the APOE--ε2 allele does not extend to an enrichment in centenarians (OR=1.08, p=0.66), although a weak enrichment of the APOE--ε2/ε3 genotype was observed (OR=1.4 p=1.7x10 --2 ) [58] . In contrast, we observed that the APOE--ε2 allele was strongly enriched in cognitively healthy centenarians from the 100--plus Study cohort compared to their birth cohort at 60--80--years: centenarians were 2.1--fold more likely to carry the APOE--ε2 allele (p=4.8x10 --7 ), and 2.5--fold more likely to have an APOE--ε2/ε3 genotype (p=3.4x10 --7 ). This confirms previous suggestive findings in a cohort of Italian centenarians who were free of dementia or any other major age--related conditions, which had a similar enrichment of the APOE--ε2 allele [62] .
We speculate that this enrichment of the APOE--ε2 allele is not a consequence of our selection of extreme ages, but that it reflects our selection of individuals with retained (cognitive) health until extreme ages.
The specific enrichment of the APOE--ε2 in the centenarians with high cognitive performance suggests that the etiology for reaching 100 years with maintained (cognitive) health may be distinct from the etiology of reaching 100 years in general.
Our results indicate that while searching for (genetic) factors that maintain cognitive health, the APOE genotype should be taken into account.
Centenarians came, on average, from higher socio--economic classes and had higher levels of education: On average, centenarians came from a higher socio--economic background than their birth cohort. A high fraction of centenarian--fathers were farmers, mostly on their own farm, a common occupation in the Netherlands during the early twentieth century. As adults, centenarians attained a higher socio--economic status and they had significantly more children compared to their birth--cohort. Both male--and female--centenarians attained higher levels of education than the males and females from their birth--cohorts. These findings reflect the selective survival advantage of individuals from the higher/middle socioeconomic classes and farmers, during the majority of the twentieth century in the Netherlands [63] . Together, this is in agreement with results from several centenarian studies, which showed that socioeconomic background, educational attainment, and adult socioeconomic status influenced the chance to become a centenarian [64] . Likewise, having children associates with an increased chance of reaching extreme ages, likely due to the involvement of children in the care for their aged parent [65] .
Alcohol consumption of centenarians was similar to birth cohort peers, and they smoked --but less: Two--thirds of the centenarian males and 15% of the centenarian females indicated to have smoked regularly or often during an extended period in their life. This was less than their birth--cohort peers, of whom almost all males and a third of the females smoked [38] . Alcohol consumption of the centenarians was similar to their birth cohorts. These results are partly in agreement with lifestyle behaviours from the American Ashkenazi Jewish centenarians, whose alcohol consumption and smoking behaviour was not different from the general population [66] .
We note that comparisons of lifestyle habits such as alcohol consumption and smoking rely on recall of habits they had several decades ago, which may introduce recall bias.
For this reason, we focused on investigating lifestyle factors that are manifest for a longer period during a lifetime. Habits that may be more variable throughout life, such as dietary or exercise habits, might be more difficult to recall and we chose to refrain from investigating these. Despite limitations, the collected statistics can be applied in within--cohort analyses, such that they add to the rich phenotypic data available for this cohort.
Conclusions:
The 100--plus Study cohort represents cognitively healthy Dutch centenarians. Compared to their birth--cohort peers, centenarians from this cohort attained significantly higher levels of education, were from a higher socioeconomic background, attained higher socioeconomic status, and they had more children, all of which confirms previous findings that these factors are associated with the chance of reaching 100 years in cognitive health. The combined contributions of these features, which are often concentrated within families, and the enrichment with the genetically heritable APOE--ε2 allele, will most likely explain a considerable proportion of the high heritability of reaching 100 years in maintained cognitive health. However, these features do not apply to all centenarians, and only a third of the cohort carries the APOE--ε2 allele. This suggests that additional protective factors may account for the cohort phenotype.
With the recent developments in biotechnology novel findings regarding the pathophysiology of exceptional longevity and cognitive function are emerging [67, 68] .
To advance such findings, the availability of blood and brain tissues of extensively phenotyped centenarians with the best possible aging--outcome and their family members, provides the opportunity to acquire insights in the molecular constellations associated with the long--term maintenance of cognitive health. Ultimately, with this cohort we aim to contribute to the generation of novel hypotheses regarding the generation of novel therapeutic targets that offer resilience to cognitive decline. Sven van der Lee for critically reviewing the manuscript before submission.
BOX: Study Rationale
The design of an intervention for neurodegenerative diseases requires not only the understanding of the neurodegenerative processes involved, but also a deep comprehension of the processes that maintain cognitive health during ageing. Although increasing age is the strongest predictive factor for cognitive decline and dementia, some people live to be over 110 years in great mental health. A Dutch woman, Hendrikje van Andel--Schipper (1890--2005), reached the age of 115 with full cognitive abilities [3] and showed that it is possible to reach extreme ages without any symptoms of cognitive decline. Her remarkable case became the source of inspiration for the initiation of the 100--plus Study at the VUmc Alzheimer Center in 2013. To investigate the pathophysiology of her extended cognitive health, it is necessary to compare her clinical characteristics with those from other individuals with the same extraordinary combination of phenotypes: extremely old and cognitively healthy. Below, we provide a rationale for researching protective factors against cognitive decline in cognitively healthy centenarians, based on the increase in mortality rate and dementia incidence in their birth cohort during its process of aging.
______
The number of centenarians in the Netherlands is growing quickly: on January 1 st 2013 there were 1940 centenarians in the Netherlands, which grew to 2,225 centenarians by 2017, and this number is expected to rise to 5,000 by 2035 [51] . Of the individuals born between 1910--1915, approximately 1:160 (0.6%) have reached ages ≥100 years [69] . When the cohort was 40 years old, the mortality resulting from natural decline rose above the rate of incidental deaths, and increased in the log scale according to Gompertz Law (1825) [76] . (G) During natural decline of the 1912 birth cohort, the males had a higher mortality rate than females, and this mortality gender gap ultimately resulted in a 1:7 male/female ratio at age 100 [51] . Approximately 70% of the mortality gender gap in these cohorts can be explained by the difference in smoking behavior between males and females [77] : an estimated 91% of all males born in 1912 smoked while only 30% of the females smoked, which ultimately led to a relative increased incidence of fatal smoking--related diseases in males. The remainder of the mortality gender gap may be explained by biological or environmental differences between males and females [78] . (H) At 100 years old, the 1912 cohort has reduced to ±1,000 persons and the mortality year for both males and females is at 40%.
(I) Individuals from the 1910--1915 birth cohorts were exposed to an increasing incidence of overall dementia from age 60 years onwards, of which the greatest proportion was (J) Alzheimer's Dementia (AD) [1] . (K) At approximately 100 years, the annual incidence of dementia reaches ~40%, and surpasses the mortality per year at that age (also ~40%), suggesting that after turning 100 years, a centenarian is exposed to greater odds of developing dementia than to die [6] . (L 1 ) If dementia incidence after 100 years continues to increase with the same exponential rate as before, following the Gompertz law of natural decline [76] , then, a conservative estimation of dementia incidence (by concentrating mortality on incident dementia cases) suggests that all individuals who reach 108--110 years would have to be demented. (L 2 ) In contrast, reports of individuals who are older than 110 years indicate that the majority of such individuals has in fact retained their cognitive health [3--5] . Therefore, it is likely that the incidence of dementia decelerates or even declines at extreme ages [6] . Although the slope of the incidence rate suggested by Corrada et al. (red dots in Figure) is slightly smaller compared to the extrapolated incidence (dashed line), there currently is no clear evidence for this deceleration between 90 and 100 years [2, 79] , it is most likely that this deceleration becomes evident somewhere after 100 years. This line of reasoning is consistent with findings in super--centenarians by Andersen et al. [5] , who demonstrated the progressive compression of both disability and morbidity (in 6 diseases including dementia) with survival beyond 100 years. Together, this suggests that factors that preserve (cognitive) health may be progressively enriched for during healthy aging [7] , providing a window of opportunity to search for such protective factors in a population of healthy (super--)centenarians.
Figure Box: Mortality and dementia incidence in centenarian birth cohort.

Blue line: Male mortality. Shades of blue represent mortality confidence intervals (CI) by
10--percentile increments [80] ; For ages 0--59 years we used only the mortality statistics of individuals born in 1912 (as to avoid blurring specific mortality peaks), and for ages 60--100 years we combined statistics of the 1910--1915 birth cohorts, which reduced CI.
Mortality after age 100 years was extrapolated according to Gompertz' law of mortality [81] . Purple line: Female mortality with CIs [80] . Red line: Median incidence of overall dementia with CIs for age groups 55--59,  60--64,  65--65,  70--74,  75--79,  80--84,  85 --89 years [1] . To define mean age per age--group, we assumed that the ages of the individuals that constituted each age--group were distributed according to associated mortality statistics. [2] . Green line: Alzheimer's Disease (AD) incidence with CIs [1] . Dashed red line: extrapolation of dementia incidence according to its exponential increase. To extrapolate dementia incidence, we fitted a Gompertz curve on available dementia incidence data [1, 2] . For the reported age ranges we compared the estimated dementia incidence with the reported incidence through a binomial distribution. This resulted in a log--likelihood, which was optimized.
FIGURES AND TABLES:
Fig. 1 Overview of the 100--plus Study, Phase 2
During home visits we inquire about life--history of the centenarians, their family history, medical history, and current health. We assess their performance on neuropsychological tests, measure blood pressure and grip strength and we collect a blood sample, for blood testing and genetic analyses. Optional parts of the study are: a visit to the VUmc clinic for PET--MRI and/or PET--CT imaging, feces donation to investigate the gut microbiome, and the generation of iPS cells from peripheral blood. Furthermore, all participants are informed about the option of post--mortem brain donation in collaboration with the Netherlands Brain Bank [34] . This is optional and not required for study participation.
We evaluate changes in general well--being and in neuropsychological test performance during (half--)yearly follow--up visits. Next to the centenarians, we also include their first-degree family members and their partners. * Collected in Phase--2 of the 100--plus Study, started in September 2017. 1 Half yearly follow--up by telephone is performed for centenarians who agreed to brain donation. 2 Collected in phase--2 of the 100--plus Study, started in September 2017. 3 Data from centenarian--children and children in--laws will be obtained during the visit with the centenarian. 
Fig. 2 Diagram of visit procedures of 100--plus Study
Fig. 3 Data collection from centenarians and their family--members
In Phase--2 of the 100--plus Study (September 2017), we obtain blood--samples from centenarians (yellow), and when willing, their siblings, their children (green) and their respective partners (purple). We will inquire about longevity and incidence of dementia in relatives from the same generation as the centenarian (white). Square: male, circle: female, diamond: both genders are possible. urinary tract infections (6.7%); urge incontinence, catheter (6.2%); prostate hypertrophy benign (with/without surgery) (4.8%); neurological/psychiatric disease (15.8%) epilepsy, insomnia, migraine (5.3%); balance problems, dizziness (3.8%); depression, loneliness (2.9%); delirium after infection or fracture (1.9%); Parkinson's disease (1.9%), starting cognitive decline (1.9%); gastrointestinal (14.8%) kidney stones (removed), renal failure (6.7%); diverticulitis, (bleeding) ulcers, polyps, stomach bleeds, appendectomy (5.7%); resection gall bladder, removal gall stones (2.4%); lung disease (10.5%) pneumonia (5.3%); COPD (5.3%); Other erysipelas, chronic leg ulcer, pericarditis (4.3%); hysterectomy, prolapse, cysts removal (4.3%); cholesteatoma (0.5%); anemia (1.0%); restless legs (1.0%); (48, 88, 19) 119 (11, 102, 6) 
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